The number of acquired changes in the genetic material of tumor tissue, the so-called tumor mutation burden (TMB), is used by oncologists as a biomarker to predict which patients could benefit from immunotherapy. There are now a variety of tests on the market allowing scientists to draw conclusions about TMB by analyzing several hundred genes. Scientists have now evaluated six genetic tests for reliability and have demonstrated that these multi-gene panels are suitable for use in routine clinical diagnostics.